CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, announced today that UnitedHealthcare commercial plans will cover FoundationOne®CDx as a ...

FoundationOne Liquid CDx can be used to identify niraparib and abiraterone acetate eligibility in patients with metastatic castration-resistant prostate cancer (mCRPC). According to the American ...

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®Liquid CDx to be used as a companion ...

“With such a rapidly evolving therapeutic landscape in prostate cancer, high-quality companion diagnostics are important tools to support oncologists in the development of personalized treatment plans ...

First and only company with 100 approved and active companion diagnostic indications for next-generation sequencing in the United States and Japan, setting the standard for high-quality genomic ...

The FDA approved Foundation Medicine’s cancer gene test Thursday. CMS also proposed national coverage of the test for Medicare beneficiaries with advanced cancer. The FoundationOne CDx is an in vitro ...

BOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (PMVP) (NASDAQ: PMVP; “PMV Pharma”) today announced a partnership to develop ...

Foundation Medicine, Inc., today announced the U.S. launch of FoundationOne ® RNA, a tissue-based RNA sequencing test for the detection of cancer-related fusions across 318 genes. FoundationOne RNA ...

Boca Raton, Fla.-based Cancer Treatment Centers of America and Foundation Medicine are collaborating on an educational campaign to raise awareness regarding the potential of precision medicine.

BOSTON & EL MONTE, Calif.--(BUSINESS WIRE)-- Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced plans to launch two new germline tests, ...